European Innovation Council (EIC)

About this programme

It supports all stages of innovation from R&D on the scientific underpinnings of breakthrough technologies, to validation and demonstration of breakthrough technologies and innovations to meet real world needs, to the development and scaling up of start-ups and small and medium-sized enterprises (SMEs).

The funding and support consists of three main funding schemes:

  • the EIC Pathfinder for advanced research to develop the scientific basis to underpin breakthrough technologies
  • the EIC Transition to validate technologies and develop business plans for specific applications
  • the EIC Accelerator to support companies (SMEs, start-ups, spin-outs and in exceptional cases small mid-caps) to bring their innovations to market and scale up.

In each funding scheme, the direct financial support to innovators is augmented with access to a range of Business Acceleration Services. The three main EIC instruments offer both bottom-up calls and calls with predefined thematic priorities (challenges). In addition to these instruments there are the EIC Prizes, which reward innovative solutions offered by companies/organisations for pre-defined societal challenges or specific target audiences, such as women innovators, innovative cities, public or private procurers or social innovation.

Click to read more 
Hide text 

Your NCP contacts for this programme

Accelerator & Transition
Image of Magali Parent

Magali Parent

magali.parent@vlaio.be

+32 2 432 42 42

Transition & Pathfinder
Image of Ria De Breucker

Ria De Breucker

Ria.debreucker@vlaio.be

+32 2 553 13 77

Latest news

Upcoming events

Work Programme & Calls

We offer a handy Excel file, weekly updated, containing an up-to-date overview of the Horizon Europe calls. call topics overview

Infosheets

Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.